Evidence map›Paper›PMID 26925265›Full record

ArticleChemotherapy research and practice2016

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.

Govind Babu, Smitha Carol Saldanha, Lakshmaiah Kuntegowdanahalli Chinnagiriyappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Loknatha Dasappa, Pretesh Rohan Kiran, Aparna Sreevatsa, Sandhya Appachu, Vineetha Unnikrishnan and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemotherapy research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 6 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 6 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
    Trial
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Govind BabuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Smitha Carol SaldanhaDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Lakshmaiah Kuntegowdanahalli ChinnagiriyappaDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Linu Abraham JacobDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Suresh Babu MallekavuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Loknatha DasappaDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Pretesh Rohan KiranDepartment of Community Health, St. John's Medical College, Bangalore 560034, India.
Aparna SreevatsaDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Sandhya AppachuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Vineetha UnnikrishnanDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Venugopal ArrojuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Kidwai Memorial Institute of Oncology · INSt.John's Medical College Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background. The efficacy, safety, and cost benefit of olanzapine (OLN) when compared to aprepitant (APR) in the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) were evaluated. Methods. A prospective pilot study was done in chemotherapy-naive patients receiving HEC to compare OLN versus APR along with palonosetron and dexamethasone. 100 patients consented to the protocol and were randomized and evaluated for Complete Response (CR) (no emesis, no rescue). Results. CR was 86% for the acute period, 86% for the delayed period, and 80% for the overall period in 50 patients receiving the APD regimen. CR was 84% for the acute period, 88% for the delayed period, and 78% for the overall period for 50 patients receiving the OPD regimen. Patients without nausea were APD: 88% acute, 84% delayed, and 84% overall, and OPD: 84% acute, 88% delayed, and 84% overall. There were no significant grade 3 or 4 toxicities. OPD was comparable to APD in the control of CINV. Conclusion. In this study, there was no significant difference between olanzapine and aprepitant in preventing CINV with highly emetogenic chemotherapy. Olanzapine may thus be used as a potential, safe, and cost beneficial alternative to prevent nausea and vomiting in HEC.

Identifiers

PMID26925265
PMCPMC4748067
OpenAlexW2269947642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.